New Strides CEO Puts Emphasis On Execution
Q3 Revenues Up 29% Led By US, UK
Strides' newly-appointed CEO, R Ananthanarayanan, sees no reason to change course as the firm's current strategy continues to yield positive results. The company posted a 29% increase in third-quarter revenues on the back of 62% growth in the US.
You may also be interested in...
Strides Optimistic On COVID-19 Antivirals
Optimistic about the potential of repurposing its antivirals portfolio, Strides plans to soon begin bioequivalence studies for favipiravir, a molecule that has found favor as a COVID-19 therapy in a few countries. It also aims to introduce new products to fill the gap left by the withdrawal of ranitidine from the US market.
Strides Acquires 18 ANDAs From Pharmaceutics
Strides has acquired 18 ANDAs from Pharmaceutics International, as well as exclusive marketing rights to a levothyroxine sodium candidate. Through this agreement, the Indian company plans to expand its niche offerings.
Strides’ New CEO Is Former Cipla COO
Arun Kumar is stepping down as chief executive of Strides Pharma to focus on overall corporate strategy and the company’s return to injectables. He will be replaced by former Cipla chief operating officer R Ananthanarayanan.